OTTAWA, May 16 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or
"the Company"), a Canadian biotechnology company developing novel compounds to
treat cancer, today announced results from the initial phase of testing of the
Company's lead cancer drug, PhGalpha1, at Memorial Sloan-Kettering Cancer
Center ("Memorial Sloan-Kettering") in New York City. In testing undertaken under the direction of Dr. Gary Schwartz at
Memorial Sloan-Kettering, PhGalpha1 was shown to increase the effect of a
commonly used chemotherapeutic drug in killing cancer cells by approximately
50%.
